FrancophonIA/ELRC3.0 huggingface dataset:
English: Very common side effects (may affect more than 1 in 10 people): - breathing problems (including shortness of breath), - feeling depressed - trouble sleeping, thinking or concentrating, dizziness, - severe stomach pain or cramps, - fever or chills beginning after a few weeks of treatment, - painful or inflamed muscles (sometimes severe),
Slovenian: Zelo pogosti neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov): - težave z dihanjem (vključno s kratko sapo), - depresija, - težave s spanjem, mišljenjem ali koncentracijo, omotica, - hude želodčne bolečine ali krči, - zvišana telesna temperatura ali mrzlica, ki se začne po nekaj tednih zdravljenja, - bolečine v mišicah ali vnetje mišic (včasih hudo).
English: Photosensitivity reaction, rash maculo-papular, skin exfoliation, pigmentation disorder, dermatitis atopic, skin discolouration Musculoskeletal and connective tissue disorders Very common:
Slovenian: preobčutljivostne reakcije na svetlobo, makulopapulozni izpuščaj, luščenje kože, motnje pigmentacije, atopični dermatitis, sprememba barve kože Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo pogosti:
English: Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
Slovenian: Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, multiformni eritem Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo pogosti:
English: 2.5 x ULN
Slovenian: 2,5 x ZMN
English: Sarcoidosis
Slovenian: sarkoidoza
English: Injection site necrosis
Slovenian: nekroza na mestu injiciranja
English: Co-administration of thioridazine with the product (ViraferonPeg) may increase the blood concentrations of thioridazine.
Slovenian: Sočasna uporaba tioridazina z zdravilom ViraferonPeg lahko zviša koncentracije tioridazina v krvi.
English: How to use ViraferonPeg
Slovenian: Kako uporabljati zdravilo ViraferonPeg
English: Pull back the plunger very slightly with one hand.
Slovenian: Z drugo roko zelo narahlo potegnite bat ven.
English: After administering the dose, discard the ViraferonPeg pre-filled pen (CLEARCLICK) and any unused solution contained in it.
Slovenian: Po uporabi neporabljene ostanke napolnjenega injekcijskega peresnika ViraferonPeg (CLEARCLICK) in raztopino, ki je ostala v njem, zavrzite.
English: Immuno-suppressive therapy
Slovenian: imunosupresivno zdravljenje
English: When patients are administered ViraferonPeg with medications metabolized by CYP1A2 or CYP2D6, the extent of the decrease in cytochrome P 450 activity is unlikely to have a clinical impact, except with medicines which have a narrow therapeutic margin (Table 5).
Slovenian: Obseg zmanjšanja aktivnosti citokroma P 450 verjetno nima kliničnega vpliva, kadar bolniki sočasno prejmejo zdravilo ViraferonPeg in zdravila, ki se presnovijo s CYP1A2 ali CYP2D6, razen pri zdravilih z ozkim terapevtskim oknom (preglednica 5).
English: Replace the needle guard and place the syringe with the needle on a flat surface.
Slovenian: Nataknite zaščitni pokrovček nazaj na iglo in brizgo z iglo položite na ravno podlago.
English: The lowest ViraferonPeg strength available is 50 g/0.5 ml; therefore for patients prescribed 0.5 g/kg/week, doses must be adjusted by volume as shown in Table 2.
Slovenian: Bolnikom, ki jim predpišete odmerek 0,5 g/kg/teden, morate torej volumsko prilagoditi odmerek, kot je prikazano v preglednici 2.
English: Adults - Dose to be administered
Slovenian: Odrasli - odmerek za injiciranje
English: Subjects treated with ViraferonPeg showed mild dose-related elevations in body temperature.
Slovenian: Pri osebah, ki so se zdravile z zdravilom ViraferonPeg, so ugotovili blago, od odmerka odvisno zvišanje telesne temperature.
English: Carton 80 micrograms
Slovenian: Škatla 80 mikrogramov
English: ViraferonPeg - ampoule of solvent
Slovenian: ViraferonPeg - ampula vehikla
English: Refer to the SmPC for boceprevir.
Slovenian: Trojna terapija Glejte SmPC za boceprevir.
English: 9/l, and < 0.75 x 10
Slovenian: 9/l in < 0,75 x 10
English: - Patients with detectable but ≥ 2 log decrease in HCV-RNA level from baseline at treatment week 12 should be reassessed at treatment week 24 and, if HCV-RNA is undetectable, they should continue with full course of therapy (i.e. a total of 48 weeks).
Slovenian: - Pri bolnikih, ki imajo merljivo koncentracijo HCV-RNA, vendar v 12. tednu zdravljenja za ≥ 2 log manjšo koncentracijo kot v izhodišču, pa je treba oceno ponoviti v 24. tednu zdravljenja in, če postane do tedaj koncentracija HCV-RNA nemerljiva, naj nadaljujejo z zdravljenjem do polnega ciklusa (tj. skupaj 48 tednov).
English: SN: NN
Slovenian: NN:
English: Geometric Mean Ratio (Ratio with/without peginterferon alfa-2b)
Slovenian: Razmerje geometričnih sredin (razmerje z/brez peginterferona alfa-2b) AUC (90 % IZ)
English: Cases of hepatitis B re-activation (some with severe consequences) have been reported in patients coinfected with hepatitis B and C viruses treated with interferon.
Slovenian: Pri bolnikih, zdravljenih z interferoni, ki so bili sočasno okuženi z virusoma hepatitisa B in C, so poročali o primerih reaktivacije hepatitisa B (nekaterih s hujšimi posledicami).
English: Abdominal pain, abdominal pain upper, vomiting, nausea
Slovenian: bolečine v trebuhu, bolečine v zgornjem delu trebuha, bruhanje, navzea
English: a: p value based on Cochran-Mantel Haenszel Chi square test. b: p value based on chi-square test. c: subjects < 75 kg received 100 µg/week ViraferonPeg and subjects ≥ 75 kg received 150 µg/week ViraferonPeg.
Slovenian: mio i.e. = milijonov mednarodnih enot a: vrednost p na podlagi Cochran-Mantel Haenszelovega hi-kvadrat testa b: vrednost p na podlagi hi-kvadrat testa c: preiskovanci s telesno maso < 75 kg so prejemali 100 µg zdravila ViraferonPeg na teden, preiskovanci s telesno maso ≥ 75 kg pa so prejemali 150 µg zdravila ViraferonPeg na teden d: odmerek ribavirina je znašal 800 mg za bolnike s telesno maso < 60 kg, 1.000 mg za bolnike s telesno maso 60 - 75 kg in 1200 mg za tiste s telesno maso > 75 kg
English: ViraferonPeg (100 or c µg/week) + ribavirin
Slovenian: ViraferonPeg (100 ali µg/teden) + ribavirin mg)
English: Carton 120 micrograms
Slovenian: Škatla 120 mikrogramov
English: Standard haematologic tests, blood chemistry and a test of thyroid function must be conducted in all patients prior to initiating therapy.
Slovenian: Pred začetkom zdravljenja morate pri vseh bolnikih opraviti standardne hematološke in biokemične krvne preiskave ter preiskavo delovanja žleze ščitnice.
English: - Stand the vial upright and let any bubbles present in the solution rise to the top of the solution.
Slovenian: Vialo postavite pokonci in pustite, da vsi mehurčki v raztopini splavajo na gladino.
English: Table 3c Reduced ViraferonPeg dose (0.5 g/kg) for the 1.0 g/kg monotherapy regimen in adults Body weight (kg)
Slovenian: Preglednica 3c Zmanjšani odmerek zdravila ViraferonPeg (0,5 g/kg) pri monoterapiji z 1,0 g/kg pri odraslih bolnikih
English: Genotype 1 > 600,000 IU/ml
Slovenian: Genotip 1 > 600.000 i.e./ml vsi
English: Carton 100 micrograms
Slovenian: Škatla 100 mikrogramov
English: Dysphonia, epistaxis, respiratory disorder, respiratory tract congestion, sinus congestion, nasal congestion, rhinorrhea, increased upper airway secretion, pharyngolaryngeal pain
Slovenian: disfonija, epistaksa, bolezni dihal, kongestija sluznice dihal, kongestija sluznice sinusov, kongestija nosne sluznice, rinoreja, povečana sekrecija v zgornjih dihalih, bolečine v žrelu in grlu
English: Adults - Duration of treatment - HCV/HIV co-infection Bitherapy: The recommended duration of treatment for HCV/HIV co-infected patients is 48 weeks with bitherapy, regardless of genotype.
Slovenian: Priporočena dolžina zdravljenja z dvojno terapijo pri bolnikih, ki so sočasno okuženi s HCV/HIV, je 48 tednov, ne glede na genotip.
English: Carton 50 micrograms
Slovenian: Škatla 50 mikrogramov
English: Seek emergency care if you notice that you are becoming depressed or have suicidal thoughts or change in your behaviour.
Slovenian: Če opazite, da postajate depresivni oz. imate samomorilne misli oz. se je vaše obnašanje spremenilo, morate poiskati nujno medicinsko pomoč.
English: Patients with severe renal dysfunction (creatinine clearance 15-29 ml/minute) should have the starting dose of ViraferonPeg reduced by 50 %.
Slovenian: Pri bolnikih z zmernimi motnjami delovanja ledvic (očistek kreatinina od 30 do 50 ml/minuto) začetni odmerek zdravila ViraferonPeg zmanjšajte za 25 %, pri tistih s hudimi motnjami delovanja ledvic (očistek kreatinina od 15 do 29 ml/minuto) pa morate začetni odmerek zdravila ViraferonPeg zmanjšati za 50 %.
English: Seek medical help immediately in case of a severe allergic reaction (such as difficulty in breathing, wheezing, or hives).
Slovenian: Če se pojavi huda alergijska reakcija (npr. težave z dihanjem, piskanje v pljučih ali koprivnica), nemudoma poiščite zdravniško pomoč.
English: No pharmacokinetic interactions were noted between ViraferonPeg and ribavirin in a multiple-dose pharmacokinetic study.
Slovenian: V študiji uporabe večkratnih odmerkov niso opažali nikakršnih farmakokinetičnih interakcij med zdravilom ViraferonPeg in ribavirinom.
English: HCV-RNA negative or ≥ 2 log decrease in viral load
Slovenian: Negativna HCV-RNA ali zmanjšanje virusnega bremena za ≥ 2 log
English: Acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) have been observed rarely during interferon alfa-2b therapy.
Slovenian: Med zdravljenjem z interferonom alfa-2b so redko opažali akutne preobčutljivostne reakcije (npr. urtikarijo, angioedem, bronhokonstrikcijo, anafilaktične reakcije).
English: Hearing impaired/loss, tinnitus, vertigo
Slovenian: poslabšanje ali izguba sluha, tinitus, vrtoglavica
English: Amount of ViraferonPeg to administer (g)
Slovenian: Količina zdravila ViraferonPeg za injiciranje (g)
English: Gently turn the pre-filled pen up-side-down two times to mix (see Figure 2).
Slovenian: Zdravilo premešajte tako, da napolnjeni injekcijski peresnik dvakrat nežno obrnete na glavo in nazaj (glejte sliko 2).
English: *Genotype 1 receive 48 weeks treatment **Genotype 2, 3 receive 24 weeks treatment ***The presented results are from a single point of time.
Slovenian: ** Genotipa 2 in 3 prejmeta 24 tednov zdravljenja.
English: Reminder: Please also read the “Do not take” section of the Package Leaflet for ribavirin and boceprevir before using them in combination with this medicine.
Slovenian: Opozorilo: Prosimo, preberite tudi poglavje "Ne uporabljajte zdravila" v navodilih za uporabo ribavirina in boceprevirja, preden ju začnete uporabljati v kombinaciji s tem zdravilom.
English: Predictability of sustained virological response - Naïve patients: Virological response by week 12 is defined as at least 2-log viral load decrease or undetectable levels of HCV-RNA.Virological response by week 4 is defined as at least 1-log viral load decrease or undetectable levels of HCV-RNA.
Slovenian: Napoved trajnega virološkega odziva - Predhodno nezdravljeni bolniki Virološki odziv do 12. tedna je opredeljen kot zmanjšanje virusnega bremena za vsaj 2 logaritemski enoti ali nemerljiva koncentracija HCV-RNA.
English: Vomiting *, nausea, abdominal pain, diarrhoea, dry mouth*
Slovenian: *, navzea, trebušne bolečine, driska, suha usta
English: You must use an effective birth control during the time you are taking ribavirin and for 4 months after stopping treatment.
Slovenian: V času jemanja ribavirina in še 4 mesece po zaključku zdravljenja morate uporabljati učinkovito kontracepcijo.
English: 9/l, and < 50 x 10
Slovenian: 9/l in < 50 x 10
English: 3 mcg/kg/week (2 weeks)
Slovenian: 3 mcg/kg/ teden (2 tedna)
English: Monotherapy with ViraferonPeg and bitherapy with ViraferonPeg and ribavirin Naïve patients
Slovenian: Monoterapija z zdravilom ViraferonPeg in dvojna terapija z zdravilom ViraferonPeg in ribavirinom: Predhodno nezdravljeni bolniki
English: Patients were randomized to receive either ViraferonPeg (100 or 150 µg/week based on weight) plus ribavirin (800-1,200 mg/day based on weight) or interferon alfa-2b (3 MIU TIW) plus ribavirin (800-1,200 mg/day based on weight).
Slovenian: Bolnike so naključno razporedili bodisi v skupino, ki je prejemala zdravilo ViraferonPeg (100 ali 150 µg/teden glede na telesno maso) in ribavirin (8001.200 mg/dan glede na telesno maso), ali pa v skupino, ki je prejemala interferon alfa-2b (3 milijone i.e. trikrat na teden) in ribavirin (800-1.200 mg/dan glede na telesno maso).
English: No paediatric subjects with SVR had relapsed during the 5 years of follow-up.
Slovenian: Med 5-letnim spremljanjem ni bilo ponovitve pri nobenem pediatričnem preiskovancu s SVR.
English: ViraferonPeg strength (g/0.5 ml)
Slovenian: Jakost zdravila ViraferonPeg (g/0,5 ml)
English: A small volume is lost during preparation of ViraferonPeg for injection when the dose is measured and injected.
Slovenian: Med pripravo zdravila ViraferonPeg za injiciranje se izgubi malo raztopine, in sicer pri merjenju in injiciranju odmerka.
English: Therefore, each vial contains an extra amount of solvent and ViraferonPeg powder to ensure delivery of the labeled dose in 0.5 ml of ViraferonPeg, solution for injection.
Slovenian: Zato vsaka viala vsebuje dodatno količino vehikla in praška ViraferonPeg, da zagotovimo dajanje odmerka, ki je naveden na nalepki, v 0,5 ml zdravila ViraferonPeg, raztopina za injiciranje.
English: SVR after treatment of chronic HCV with ViraferonPeg (with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical “cure” from chronic HCV.
Slovenian: Doseganje trajnega virološkega odziva po zdravljenju kroničnega HCV z zdravilom ViraferonPeg (z ali brez ribavirina) vodi do dolgoročne odstranitve virusa, s čimer zagotovimo odpravo jetrne okužbe in klinično "ozdravitev" kronične okužbe s HCV, vendar pri bolnikih s cirozo jeter seveda ni izključeno kasnejše pojavljanje različnih jetrnih težav (na primer karcinoma jeter).
English: Metabolism of theophylline is suppressed by inhibitory action of the product (ViraferonPeg) on CYP1A2.
Slovenian: Zaviralni učinek zdravila ViraferonPeg na CYP1A2 upočasni presnovo teofilina.
English: Common side effects (may affect up to 1 in 10 people): - chest pain, changes in the way your heart beats, - confusion, - difficulty remaining alert, numbness or tingling feeling, - pain in your lower back or side, difficulty or inability to pass urine, - problems with your eyes or your eyesight or hearing, - severe or painful reddening of your skin or mucous membrane, - severe bleeding from your nose, gums or any other part of your body.
Slovenian: Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): bolečine v prsih, spremenjen srčni utrip, zmedenost, težave ostati buden, občutek omrtvičenosti ali mravljincev, bolečine v križu ali ob strani, težave pri uriniranju ali nezmožnost uriniranja, težave z očmi, vidom ali sluhom, močna ali boleča pordelost kože ali sluznic, hude krvavitve iz nosu, dlesni, ali katerega koli drugega dela telesa.
English: Therefore, you and your partner must take special precautions in sexual activity if there is any chance for pregnancy to occur: - if you are a girl or a woman of childbearing age who is taking ribavirin: you must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment is stopped.
Slovenian: Ribavirin je lahko zelo škodljiv za plod, zato morate vi in vaš partner upoštevati posebne previdnostne ukrepe glede spolnih odnosov, če obstaja kakršna koli možnost za zanositev: - če ste dekle ali ženska v rodni dobi in jemljete ribavirin:
English: Psoriasis, photosensitivity reaction, rash maculo-papular, dermatitis, erythematous rash, eczema, night sweats, hyperhidrosis, acne, furuncle, erythema, urticaria, abnormal hair texture, nail disorder
Slovenian: psoriaza, preobčutljivostna reakcija na svetlobo, makulopapulozni izpuščaj, dermatitis, eritematozni izpuščaj, ekcem, nočno potenje, hiperhidroza, akne, furunkel, eritem, urtikarija, nenormalna tekstura las, spremenjeni nohti
English: ViraferonPeg 1.5 micrograms/kg
Slovenian: ViraferonPeg 1,5 mikrograma/kg
English: You may dial up or down to any dose prior to injection.
Slovenian: Pred injiciranjem lahko nastavljeni odmerek še vedno povečate ali zmanjšate na kateri koli odmerek.
English: SVR in patients with undetectable HCVRNA at treatment week 12
Slovenian: - Pri bolnikih, ki imajo merljivo koncentracijo HCV-RNA, vendar v 12. tednu zdravljenja za
English: Retreatment duration greater than 48 weeks in non-responder patients with genotype 1 has not been studied with pegylated interferon alfa-2b and ribavirin combination therapy.
Slovenian: Pri neodzivnih bolnikih z genotipom 1 niso proučili ponovnega zdravljenja s pegiliranim interferonom alfa-2b v kombinaciji z ribavirinom, ki bi trajalo dlje kot 48 tednov.
English: Injection site reaction, injection site pruritus, injection site rash injection site dryness, injection site pain, feeling cold
Slovenian: reakcija na mestu injiciranja, pruritus na mestu injiciranja, izpuščaj na mestu injiciranja, suha koža na mestu injiciranja, bolečine na mestu injiciranja, občutek mrazenja
English: Mitochondrial toxicity and lactic acidosis have been reported in HIV-positive patients receiving NRTI regimen and associated ribavirin for co-HCV infection (see section 4.4).
Slovenian: Pri HIV-pozitivnih bolnikih, ki so prejemali režim zdravljenja z NRTI in ribavirin zaradi sočasne okužbe s HCV, so poročali o toksičnosti za mitohondrije in o laktacidozi (glejte poglavje 4.4).
English: The solvent is presented in a 2 ml ampoule (Type I flint glass).
Slovenian: Vehikel je v 2 ml ampulah (iz kristalnega stekla tipa I).
English: With one hand, pinch a fold of loose skin.
Slovenian: Z eno roko pridvignite kožo v gubo.
English: Discontinue ViraferonPeg if:
Slovenian: Ukinite zdravilo ViraferonPeg v primeru:
English: Growth and development (children and adolescents) During the course of therapy lasting up to 48 weeks in patients ages 3 through 17 years, weight loss and growth inhibition were common.
Slovenian: Med terapijo, ki je trajala do 48 tednov, sta bila pri bolnikih, starih od 3 do 17 let, pogosta hujšanje in zastoj rasti.
English: - Dissolve the entire contents by swirling the ViraferonPeg vial with a gentle rotary motion leaving the needle and attached syringe in the vial.
Slovenian: Da boste raztopili celotno vsebino viale zdravila ViraferonPeg, jo nežno obračajte skupaj z iglo na brizgi, ki je še v viali, dokler ne bo vsebina viale popolnoma raztopljena.
English: For BMI, pre-treatment to end of long-term follow-up, BMI-for-age percentiles decreased 1.8 and 7.5 percentiles among subjects treated for 24 weeks or 48 weeks, respectively.
Slovenian: Za indeks telesne mase (ITM) se je percentil ITM za starost od časa pred zdravljenjem do konca dolgoročnega spremljanja preiskovancem, zdravljenim 24 tednov, zmanjšal za 1,8 percentila in preiskovancem, zdravljenim 48 tednov, za 7,5 percentila.
English: For weight, pre-treatment to end of long-term follow-up, weightfor-age percentiles decreased 1.3 and 5.5 percentiles among subjects treated for 24 weeks or 48 weeks, respectively.
Slovenian: Za telesno maso se je percentil telesne mase za starost od časa pred zdravljenjem do konca dolgoročnega spremljanja preiskovancem, zdravljenim 24 tednov, zmanjšal za 1,3 percentila in preiskovancem, zdravljenim 48 tednov, za 5,5 percentila.
English: - Inject the solvent SLOWLY, aiming the stream of liquid at the glass wall of the vial.
Slovenian: Curek tekočine naj bo usmerjen v steno viale.
English: Rare side effects (may affect up to 1 in 1,000 people): - diabetic ketoacidosis (medical emergency due to build-up of ketone bodies in the blood as a result of out-of-control diabetes), - seizures (convulsions) and bipolar disorders (mood disorders characterized by alternating episodes of sadness and excitement), - eye problems including changes in vision, damage to the retina, obstruction of the retinal artery, inflammation of the optic nerve, swelling of the eye, - congestive heart failure, abnormal heart rhythm, pericarditis (inflammation of the lining of the heart), inflammation and degeneration of muscle tissue and peripheral nerves, kidney problems, - sarcoidosis (a disease characterized by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands).
Slovenian: Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): - diabetična ketoacidoza (nujno zdravstveno stanje s povišanim nivojem ketonov v krvi zaradi nenadzorovane sladkorne bolezni), - epileptični napadi (konvulzije) in bipolarne motnje (motnje v razpoloženju z značilnimi izmenjavami žalosti in navdušenja), - očesne težave vključno s spremembami vida, poškodbe mrežnice, obstrukcija mrežnične arterije, vnetje vidnega živca, otekanje oči, - kongestivno srčno popuščanje, motnje srčnega ritma, perikarditis (vnetje osrčnika), vnetje in degeneracija mišičnega tkiva in perifernih živcev, ledvične težave, - sarkoidoza (bolezen, za katero so značilni trdovratno zvišana telesna temperatura, hujšanje, bolečine in otekanje sklepov, kožne spremembe in otekle bezgavke).
English: Table 7 Adverse reactions very commonly, commonly and uncommonly reported in the clinical trial in children and adolescent patients treated with ViraferonPeg in combination with ribavirin
Slovenian: Preglednica 7 Neželeni učinki, o katerih so v kliničnem preskušanju pri otrocih in mladostnikih, zdravljenih z zdravilom ViraferonPeg v kombinaciji z ribavirinom, poročali zelo pogosto, pogosto ali občasno Infekcijske in parazitske bolezni
English: Loss of visual acuity or visual fields, retinal haemorrhage, retinopathy, retinal artery occlusion, retinal vein occlusion, optic neuritis, papilloedema, macular oedema
Slovenian: izguba ostrine vida ali zmanjšanje vidnega polja, krvavitev v mrežnici, retinopatija, zapora mrežnične arterije, zapora mrežnične vene, optični nevritis, edem papile, edem makule
English: Therefore, each pre-filled pen contains an excess amount of solvent and ViraferonPeg powder to ensure delivery of the labelled dose in 0.5 ml of ViraferonPeg, solution for injection.
Slovenian: Zato vsak napolnjen injekcijski peresnik vsebuje dodatno količino vehikla in praška ViraferonPeg, da zagotovimo dajanje odmerka, ki je naveden na nalepki, v 0,5 ml zdravila ViraferonPeg, raztopina za injiciranje.
English: Dapsone (N-acetyltransferase substrate)
Slovenian: dapson (substrat
English: Anaemia, leucopenia, neutropenia
Slovenian: anemija, levkopenija, nevtropenija
English: Neutrophils
Slovenian: • Nevtrofilci
English: Diarrhoea, aphthous stomatitis, cheilosis, mouth ulceration, stomach discomfort, oral pain
Slovenian: driska, aftozni stomatitis, heiloza, razjede v ustih, neugodje v trebuhu, bolečine v ustih
English: Table 2 Monotherapy dosing 0.5 g/kg
Slovenian: Preglednica 2 Odmerjanje pri monoterapiji 0,5 g/kg
English: Dental and periodontal disorders
Slovenian: Bolezni zob in obzobnega tkiva
English: Please refer to the ribavirin and boceprevir Summary of Product Characteristics (SmPCs) when ViraferonPeg is to be used in combination with these medicines.
Slovenian: V primeru uporabe zdravila ViraferonPeg z ribavirinom in boceprevirjem, prosimo, glejte Povzetka glavnih značilnosti zdravila (SmPC) za ti dve zdravili.
English: Discard any solution that is left in the vial after you give yourself the injection.
Slovenian: Morebitno raztopino, ki po injiciranju zdravila še ostane v viali, zavrzite.
English: 1 mcg/kg/week (4 weeks)
Slovenian: 1 mcg/kg/ teden (4 tedne)